Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;9(3):142-6.

Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial

Shahrokh Amiri  1 , Ayyoub Malek  1 , Farid Tofighnia  2 , Bohlool Habibi Asl  3 , Ali Seidy  2
Affiliations

Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial

Shahrokh Amiri et al. Iran J Psychiatry. 2014 Jul.

Abstract

Objective: Withdrawal symptoms are a main reason of continuous use of opioid. This study compares the efficacy of augmentation of amantadine with clonidine in decreasing opioid withdrawal symptoms.

Methods: This double-blind randomized clinical trial was carried out in the detoxification and rehabilitation inpatient ward at Razi Hospital, Tabriz, Iran during 2012. The patients were randomly assigned to receive clonidine or clonidine plus amantadine; and withdrawal symptoms were evaluated in the admission day and 24, 48, and 72 hours later. Data were analyzed using SPSS by the 2*2 repeated analyses of variances (ANOVA).

Results: From the total of 69 participants, 30 patients completed the trial in each group. The severity of symptoms, however, had an increasing trend in both groups. Analysis of variance of the symptom severity score (by The Clinical Opiate Withdrawal Scale) revealed a significant group-time interaction, and the patients who were receiving amantadine experienced milder symptoms.

Conclusions: Treatment of opioid withdrawal symptoms with amantadine and clonidine would result in a better outcome compared with clonidine alone.

Keywords: Amantadine; Clonidine; Withdrawal Syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of opioid dependent patients admitted for detoxification
Figure 2
Figure 2
Withdrawal symptom score in two groups receiving Clonidine alone or clonidine and Amantadine in continuous measurements.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Assadi SM, Hafezi M, Mokri A, Razzaghi EM, Ghaeli P. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. J Subst Abuse Treat. 2004;27:75–82. - PubMed
    1. Gold MS, Redmond DE, Jr, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet. 1978;2:599–602. - PubMed
    1. Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: a review. Int J Clin Pharmacol Ther. 2004;42:191–203. - PubMed
    1. Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl) 2001;157:1–10. - PubMed
    1. Sadock BJ, Sadock VA. Kaplan and Sadock’s Comprehensive Textbook of psychiatry. 7. Philadelphia: Lippincot Williams & Wilkins; 2000. pp. 941–1057.

LinkOut - more resources